NasdaqGS - Nasdaq Real Time Price • USD
Sanofi (SNY)
As of 2:24 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 4 | 3 |
| Avg. Estimate | 1.92 | 1.8 | 4.2 | 4.83 |
| Low Estimate | 1.92 | 1.8 | 4.15 | 4.75 |
| High Estimate | 1.92 | 1.8 | 4.25 | 4.93 |
| Year Ago EPS | 1.16 | 0.95 | 4.38 | 4.2 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 15 | 14 |
| Avg. Estimate | 11.1B | 11.32B | 49.63B | 53.16B |
| Low Estimate | 10.89B | 11.07B | 47.51B | 50.27B |
| High Estimate | 11.59B | 11.67B | 53.03B | 56.21B |
| Year Ago Sales | 11.33B | 11.23B | 46.57B | 49.63B |
| Sales Growth (year/est) | -2.00% | 0.80% | 6.60% | 7.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.1 | 0.89 | 1.37 | 0.91 |
| EPS Actual | 1.16 | 0.95 | 2.77 | 0.89 |
| Difference | 0.06 | 0.06 | 1.4 | -0.02 |
| Surprise % | 5.50% | 6.70% | 102.20% | -2.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.92 | 1.8 | 4.2 | 4.83 |
| 7 Days Ago | 1.92 | 1.8 | 4.21 | 4.85 |
| 30 Days Ago | 1.92 | 1.8 | 4.23 | 4.97 |
| 60 Days Ago | 1.91 | 1.79 | 7.74 | 8.99 |
| 90 Days Ago | 0 | 0 | 7.77 | 9.36 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SNY | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 65.50% | -- | -- | 0.80% |
| Next Qtr. | 89.50% | -- | -- | 9.60% |
| Current Year | -4.10% | -- | -- | 4.50% |
| Next Year | 15.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 9.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 13.18% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Initiated | Morgan Stanley: Equal-Weight | 1/23/2024 |
| Maintains | Argus Research: Buy | 3/27/2023 |
| Upgrade | Deutsche Bank: Sell to Hold | 8/12/2022 |
| Upgrade | SVB Leerink: Market Perform to Outperform | 9/27/2021 |
| Initiated | Deutsche Bank: Sell | 1/15/2021 |
| Upgrade | Goldman Sachs: Neutral to Buy | 3/11/2020 |
Related Tickers
NVS Novartis AG
94.08
+1.63%
GSK GSK plc
39.67
+1.01%
RHHBY Roche Holding AG
30.34
+0.95%
AZN AstraZeneca PLC
68.40
+0.05%
BMY Bristol-Myers Squibb Company
48.87
+1.17%
GILD Gilead Sciences, Inc.
66.44
+0.42%
AMGN Amgen Inc.
267.72
+1.89%
BIIB Biogen Inc.
192.53
+1.06%
MRK Merck & Co., Inc.
125.73
+0.40%
OGN Organon & Co.
17.64
-1.23%